Skip to main content
. 2022 Feb 18;17(9):e202100755. doi: 10.1002/cmdc.202100755

Figure 1.

Figure 1

A) Structures of approved HDAC inhibitors: vorinostat (FDA; CTCL), romidepsin (FDA; CTCL, PTCL), belinostat (FDA, PTCL) and panobinostat (FDA, EMA; MM), tucidinostat (NMDA; PTCL, HR+ breast cancer);[ 10 , 14 ] B) Selected class I selective HDACi. C) Cpd. 258 aa, [19] hereafter referred to as “6 c”, is an example for a HDAC1/2 inhibitor derived from CI‐994 by introducing a 2‐thienyl‐substituent as “foot‐pocket” unit (FPU).